The Source

The Source Blog

Orphan Drug Act: Fostering Innovation or Abuse?

Introduction

Luke Whitbeck, 2, was born with Gaucher disease, a rare genetic disorder.[1] Before using the pharmaceutical drug Cerezyme,[2] “Luke frequently ran high fevers, tired easily, and was s

Continue Reading

Download as PDF

Do Bundled Payments Have a Future in Medicare?

In an op-ed written for the Wall Street Journal on September 19, 2017, Seema Verma, the new administrator for the Centers for Medicare & Medicaid Services (CMS), announced a “new direction” initiative

Continue Reading

Download as PDF

Academic Articles & Reports Roundup: November 2017

Happy December! In this Roundup, we cover four articles from November. The topics this month include: (1) new methods to measure healthcare costs and (2) economic impacts of ACA repeal efforts.

Better Understanding Healthcare Costs Through the Use of New Methodologies

Continue Reading

Download as PDF

Has the Problem of Increasing Drug Prices Really Passed?

The rate of increase in spending on pharmaceuticals is declining, according to a Quintiles-IMS Health report from May of 2017.

Continue Reading

Download as PDF

California Legislative Beat: Four Chaptered Healthcare Assembly Bills You May Not Have Known About

With 2,913 resolutions and bills passed and signed by the Governor this year, the California Legislature has been busy. This month, we take a look at some Assembly Bills that have been chaptered and discuss their importance to healthcare costs and competition. Next month, we’ll look at some Senate

Continue Reading

Download as PDF

Healthcare Companies with a Conscience: How Benefit Corporations Can Reduce Healthcare Costs

As healthcare costs continue to rise from almost every angle, quality healthcare and treatment often come with a lofty price tag. Survival of private healthcare providers is contingent upon optimizing profits, such that a company’s motivation is driven by shareholder value instead of commitment to

Continue Reading

Download as PDF